Allogene Therapeutics

Update in progress

ALLO (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Allogene Therapeutics is a clinical-stage immuno-oncology company that develops and commercializes genetically engineered allogeneic CAR T cell therapies for cancer and autoimmune diseases. Its pipeline uses protein engineering, gene editing, gene insertion, and advanced manufacturing. Key programs include cema-cel (CD19) for large B-cell lymphoma, ALLO-316 (CD70) for RCC, and ALLO-329 (CD19/CD70) for autoimmune diseases such as SLE, IIM, and SSc. Founded 2017, South San Francisco.

Company score

Sentiment: -0.29; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.42; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.15; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.22; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive